Owkinews: What happened in February?
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395
OKN4395 is a highly selective triple inhibitor of EP2/EP4 and DP1, with a first-in-class profile targeting select solid tumors in patients with high unmet need.
OKN4395 is the first Owkin development program to leverage Owkin’s AI operating system to optimize the clinical development strategy, by building a detailed biological understanding of the EP2/EP4/DP1 targets and their complex mechanisms of action.
Owkin and Servier deliver moonshot glioblastoma hackathon
We brought together 100+ researchers, data scientists, clinicians and engineers from 29 countries to advance glioblastoma research. With new ideas, new AI models and new ways of analyzing data, we reimagined how we understand glioblastoma.
Supported by Amazon Web Services (AWS) , 10x Genomics , Bioptimus , Parker Institute for Cancer Immunotherapy , MOSAIC research , and La Place Fintech | DeFi .
The Wall Street Journal: Can AI help Pharma speed up drug development?
Our CEO, Thomas Clozel , features alongside leaders from AstraZeneca, Genentech, and GSK in this article exploring the transformative role of AI in drug development - the opportunities and challenges that drive change in the pharmaceutical industry.
How are spatial biology and AI shaping the future of ADCs?
We partnered with 10x Genomics to host a webinar exploring how spatial omics and AI accelerate antibody-drug conjugate (ADC) development in precision medicine. Stay tuned for the on-demand video.
And in our companion blog, we break down the opportunities and the challenges of ADCs, why Pharma is heavily investing in ADCs and how Owkin K’s agentic AI can supercharge ADC development strategies.